V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.
Maheswari Senthil,Preeti Chaudhary,David D. Smith,Patrick E. Ventura,Paul Frankel,Vinod Pullarkat,Vijay Trisal +6 more
TL;DR: Cancer patients undergoing catheter placement who develop CVC-associated VTE have a shorter a PTT and aPTT ratio than those who do not develop VTE, and a simple and inexpensive test might be useful as a predictor of C VC- associated VTE risk in cancer patients.
Journal ArticleDOI
The Number Of Peg-Asparaginase Doses Administered Is a Determinant Of Relapse Risk In Adult ALL Treated With a Pediatric-Like Regimen
TL;DR: In adult patients with ALL who had remained in first remission throughout the entire induction and consolidations period of a pediatric-like regimen, less prior exposure to PEG-ASN was associated with increased late relapse risk after starting maintenance therapy, and results support the importance of ASN treatment in adult ALL.
Journal ArticleDOI
Venetoclax-containing regimens in acute myeloid leukemia.
TL;DR: Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has demonstrated exceptional activity in elderly and unfit patients with newly diagnosed acute myeloid leukemia (AML) as mentioned in this paper.
Journal Article
Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children.
TL;DR: The persistence of minimal residual disease has emerged as the single most important prognostic factor for ALL and is increasingly being used to help make decisions regarding allogeneic hematopoietic stem cell transplantation or novel salvage therapies.
Journal ArticleDOI
Deferasirox: appraisal of safety and efficacy in long-term therapy
Preeti Chaudhary,Vinod Pullarkat +1 more
TL;DR: Across various pivotal clinical trials, deferasirox was well tolerated, with the most common adverse events being gastrointestinal disturbances, skin rash, nonprogressive increases in serum creatinine, and elevations in liver enzyme levels.